These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34855251)

  • 41. Treatment approaches of advanced cutaneous squamous cell carcinoma.
    Peris K; Piccerillo A; Del Regno L; Di Stefani A
    J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():19-22. PubMed ID: 34855254
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma.
    Marques-Piubelli ML; Tetzlaff MT; Nagarajan P; Duke TC; Glitza Oliva IC; Ledesma DA; Aung PP; Torres-Cabala CA; Wistuba II; Prieto VG; Nelson KC; Curry JL
    J Cutan Pathol; 2020 Oct; 47(10):954-959. PubMed ID: 32394425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report.
    Deng C; Yang M; Jiang H; Wang R; Yang Z; Sun H; Cui H
    Front Oncol; 2021; 11():664809. PubMed ID: 34540659
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cutaneous squamous cell carcinoma (cSCC) and immunosurveillance - the impact of immunosuppression on frequency of cSCC.
    Plasmeijer EI; Sachse MM; Gebhardt C; Geusau A; Bouwes Bavinck JN
    J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():33-37. PubMed ID: 31833604
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases.
    Blum V; Müller B; Hofer S; Pardo E; Zeidler K; Diebold J; Strobel K; Brand C; Aebi S; Gautschi O
    Eur J Dermatol; 2018 Feb; 28(1):78-81. PubMed ID: 29336323
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
    Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
    Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
    Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
    Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
    Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA
    Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.
    Ashraf S; Alsharedi M
    Stem Cell Investig; 2021; 8():19. PubMed ID: 34631872
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.
    Maubec E; Boubaya M; Petrow P; Beylot-Barry M; Basset-Seguin N; Deschamps L; Grob JJ; Dréno B; Scheer-Senyarich I; Bloch-Queyrat C; Leccia MT; Stefan A; Saiag P; Grange F; Meyer N; de Quatrebarbes J; Dinulescu M; Legoupil D; Machet L; Dereure O; Zehou O; Montaudié H; Wierzbicka-Hainaut E; Le Corre Y; Mansard S; Guégan S; Arnault JP; Dalac S; Aubin F; Alloux C; Lopez I; Cherbal S; Tibi A; Lévy V;
    J Clin Oncol; 2020 Sep; 38(26):3051-3061. PubMed ID: 32730186
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management of partial and non-responding cutaneous squamous cell carcinoma.
    Jansen P; Lodde GC; Griewank KG; Hadaschik E; Roesch A; Ugurel S; Zimmer L; Livingstone E; Schadendorf D
    J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():29-34. PubMed ID: 34855242
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
    Yao L; Jia G; Lu L; Bao Y; Ma W
    Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tri-Site Academic Center Experience with Immunotherapy for Metastatic Skin Cancer in Solid Organ Transplant Patients.
    Berman HS; Degesys CA; Tolaymat L
    South Med J; 2023 Feb; 116(2):220-224. PubMed ID: 36724539
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
    Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
    Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.
    Stratigos AJ; Garbe C; Dessinioti C; Lebbe C; Bataille V; Bastholt L; Dreno B; Concetta Fargnoli M; Forsea AM; Frenard C; Harwood CA; Hauschild A; Hoeller C; Kandolf-Sekulovic L; Kaufmann R; Kelleners-Smeets NWJ; Malvehy J; Del Marmol V; Middleton MR; Moreno-Ramirez D; Pellecani G; Peris K; Saiag P; van den Beuken-van Everdingen MHJ; Vieira R; Zalaudek I; Eggermont AMM; Grob JJ;
    Eur J Cancer; 2020 Mar; 128():83-102. PubMed ID: 32113942
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab.
    Venkatesh S; Al-Haseni A; Sahni D
    BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31377718
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.
    Ahmed SR; Petersen E; Patel R; Migden MR
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):947-951. PubMed ID: 31524530
    [No Abstract]   [Full Text] [Related]  

  • 59. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
    Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of thoracic sarcoid reactions associated with complete response to anti-PD-1 therapy in a patient with advanced cutaneous squamous cell carcinoma.
    Gambichler T; Philippou S; Scheel CH; Susok L
    J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():35-40. PubMed ID: 34855255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.